SEARCH

SEARCH BY CITATION

References

  • 1
    Chen YT,Scanlan MJ,Sahin U,Tureci O,Gure AO,Tsang S,Williamson B,Stockert E,Pfreundschuh M,Old LJ. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997; 94: 191418.
  • 2
    Scanlan MJ,Gure AO,Jungbluth AA,Old LJ,Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002; 188: 2232.
  • 3
    Jager E,Stockert E,Zidianakis Z,Chen YT,Karbach J,Jager D,Arand M,Ritter G,Old LJ,Knuth A. Humoral immune responses of cancer patients against “Cancer-Testis” antigen NY-ESO-1: correlation with clinical events. Int J Cancer 1999; 84: 50610.
  • 4
    Stockert E,Jager E,Chen YT,Scanlan MJ,Gout I,Karbach J,Arand M,Knuth A,Old LJ. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998; 187: 134954.
  • 5
    Fossa A,Berner A,Fossa SD,Hernes E,Gaudernack G,Smeland EB. NY-ESO-1 protein expression and humoral immune responses in prostate cancer. Prostate 2004; 59: 4407.
  • 6
    Akcakanat A,Kanda T,Koyama Y,Watanabe M,Kimura E,Yoshida Y,Komukai S,Nakagawa S,Odani S,Fujii H,Hatakeyama K. NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer. Cancer Chemother Pharmacol 2004; 54: 95100.
  • 7
    Fujita S,Wada H,Jungbluth AA,Sato S,Nakata T,Noguchi Y,Doki Y,Yasui M,Sugita Y,Yasuda T,Yano M,Ono T, et al. NY-ESO-1 expression and immunogenicity in esophageal cancer. Clin Cancer Res 2004; 10: 65518.
  • 8
    Sahin U,Tureci O,Chen YT,Seitz G,Villena-Heinsen C,Old LJ,Pfreundschuh M. Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: basis for polyvalent CT vaccine strategies. Int J Cancer 1998; 78: 3879.
  • 9
    Mashino K,Sadanaga N,Yamaguchi H,Tanaka F,Ohta M,Shibuta K,Inoue H,Mori M. Expression of multiple cancer-testis antigen genes in gastrointestinal and breast carcinomas. Br J Cancer 2001; 85: 71320.
  • 10
    Sugita Y,Wada H,Fujita S,Nakata T,Sato S,Noguchi Y,Jungbluth AA,Yamaguchi M,Chen YT,Stockert E,Gnjatic S,Williamson B et al. NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Res 2004; 64: 2199204.
  • 11
    Odunsi K,Jungbluth AA,Stockert E,Qian F,Gnjatic S,Tammela J,Intengan M,Beck A,Keitz B,Santiago D,Williamson B,Scanlan MJ, et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res 2003; 63: 607683.
  • 12
    Gnjatic S,Atanackovic D,Jager E,Matsuo M,Selvakumar A,Altorki NK,Maki RG,Dupont B,Ritter G,Chen YT,Knuth A,Old LJ. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci USA 2003; 100: 88627.
  • 13
    Davis ID,Chen W,Jackson H,Parente P,Shackleton M,Hopkins W,Chen Q,Dimopoulos N,Luke T,Murphy R,Scott AM,Maraskovsky E, et al. Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci USA 2004; 101: 10697702.
  • 14
    Jager E,Nagata Y,Gnjatic S,Wada H,Stockert E,Karbach J,Dunbar PR,Lee SY,Jungbluth A,Jager D,Arand M,Ritter G, et al. Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci USA 2000; 97: 47605.
  • 15
    Valmori D,Souleimanian NE,Hesdorffer CS,Ritter G,Old LJ,Ayyoub M. Identification of B cell epitopes recognized by antibodies specific for the tumor antigen NY-ESO-1 in cancer patients with spontaneous immune responses. Clin Immunol 2005; 117: 2430.
  • 16
    Zeng G,Aldridge ME,Wang Y,Pantuck AJ,Wang AY,Liu YX,Han Y,Yuan YH,Robbins PF,Dubinett SM,deKernion JB,Belldegrun AS. Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: implications as a potential biomarker. Int J Cancer 2005; 114: 26873.
  • 17
    Ikuta Y,Katayama N,Wang L,Okugawa T,Takahashi Y,Schmitt M,Gu X,Watanabe M,Akiyoshi K,Nakamura H,Kuribayashi K,Sunamoto J, et al. Presentation of a major histocompatibility complex class 1-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex: implications for a polyvalent immuno-cell therapy. Blood 2002; 99: 371724.
  • 18
    Hasegawa K,Noguchi Y,Koizumi F,Uenaka A,Tanaka M,Shimono M,Nakamura H,Shiku H,Gnjatic S,Murphy R,Hiramatsu Y,Old LJ, et al. In vitro stimulation of CD8 and. CD4 T cells by dendritic cells loaded with a complex of cholesterol-bearing hydrophobized pullulan and NY-ESO-1 protein: identification of a new. HLA-DR15-binding. CD4 T-cell epitope. Clin Cancer Res 2006; 12: 19217.
  • 19
    Murphy R,Green S,Ritter G,Cohen L,Ryan D,Woods W,Rubira M,Cebon J,Davis ID,Sjolander A,Kypridis A,Kalnins H, et al. Recombinant NY-ESO-1 cancer antigen: production and purification under cGMP conditions. Prep Biochem Biotechnol 2005; 35: 11934.
  • 20
    Akiyoshi K,Kobayashi S,Shichibe S,Mix D,Baudys M,Kim SW,Sunamoto J. Self-assembled hydrogel nanoparticle of cholesterol-bearing pullulan as a carrier of protein drugs: complexation and stabilization of insulin. J Control Release 1998; 54: 31320.
  • 21
    Kawabe T,Naka T,Yoshida K,Tanaka T,Fujiwara H,Suematsu S,Yoshida N,Kishimoto T,Kikutani H. The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation. Immunity 1994; 1: 16778.
  • 22
    Abbas AK,Murphy KM,Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383: 78793.